Patents Assigned to ISIS Pharmaceuticals Inc.
  • ANTIDOTES TO ANTISENSE COMPOUNDS
    Publication number: 20130296400
    Abstract: The present invention relates to antisense antidote compounds and uses thereof. Such antidote compounds reduce the magnitude and/or duration of the antisense activity of an antisense compound.
    Type: Application
    Filed: March 4, 2013
    Publication date: November 7, 2013
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventor: Isis Pharmaceuticals, Inc.
  • COMPOUNDS AND METHODS FOR MODULATING INTERACTION BETWEEN PROTEINS AND TARGET NUCLEIC ACIDS
    Publication number: 20130289092
    Abstract: Provided herein are antisense compounds and methods for recruiting one or more non-cleaving protein to a target nucleic acid in a cell. In certain instances such recruitment of a non-cleaving protein alters the function or activity of the target nucleic acid. In certain such instances, the target nucleic acid a pre-mRNA and the recruitment of the non-cleaving protein results in a change in splicing of the pre-mRNA.
    Type: Application
    Filed: June 15, 2011
    Publication date: October 31, 2013
    Applicants: Cold Spring Harbor Laboratory, Isis Pharmaceuticals, Inc.
    Inventors: Frank Rigo, C. Frank Bennett, Adrian R. Krainer, Yimin Hua
  • Proinflammatory nucleic acids
    Patent number: 8568976
    Abstract: The present invention provides compositions and methods for identifying and utilizing proinflammatory nucleic acids. In particular, this invention relates to compounds, particularly oligonucleotides, which exert their effect through triggering receptors expressed by myeloid cells (TREMs), specifically TREM 2.
    Type: Grant
    Filed: December 12, 2011
    Date of Patent: October 29, 2013
    Assignee: Isis Pharmaceuticals, Inc.
    Inventor: Joseph Senn
  • Double stranded constructs comprising one or more short strands hybridized to a longer strand
    Patent number: 8569474
    Abstract: The present invention provides compositions comprising an antisense oligomeric compound hybridized to at least one shorter sense oligomeric compound. The sense oligomeric compounds can be covalently linked to the antisense oligomeric compounds. At least a portion of the antisense oligomeric compound is complementary to and hybridizes with a nucleic acid target. Methods for modulating gene expression are also provided using the compositions of the present invention.
    Type: Grant
    Filed: March 4, 2005
    Date of Patent: October 29, 2013
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Brenda F. Baker, Bryan A. Kraynack
  • Antibacterial 4,5-substituted aminoglycoside analogs having multiple substituents
    Patent number: 8569264
    Abstract: The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection.
    Type: Grant
    Filed: January 5, 2012
    Date of Patent: October 29, 2013
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Eric E. Swayze, Stephen Hanessian, Janek Szychowski, Susanta Sekhar Adhikari, Kandasamy Pachamuthu, Xiaojing Wang, Michael T. Migawa, Richard H. Griffey
  • COMPOSITIONS AND METHODS FOR NON-PARENTERAL DELIVERY OF OLIGONUCLEOTIDES
    Publication number: 20130274309
    Abstract: The present invention relates to compositions and methods which enhance the local and systemic uptake and delivery of oligonucleotides and nucleic acids via non-parenteral routes of administration. Pharmaceutical compositions comprising oligonucleotides disclosed herein include, for systemic delivery, emulsion and microemulsion formulations for a variety of applications and oral dosage formulations. It has also surprisingly been discovered that oligonucleotides may be locally delivered to colonic sites by rectal enemas and suppositories in simple solutions, e.g., neat or in saline. Such pharmaceutical compositions of oligonucleotides may further include one or more penetration enhancers for the transport of oligonucleotides and other nucleic acids across mucosal membranes.
    Type: Application
    Filed: January 7, 2013
    Publication date: October 17, 2013
    Applicant: Isis Pharmaceuticals, Inc.
    Inventor: Isis Pharmaceuticals, Inc.
  • CONFORMATIONALLY RESTRICTED DINUCLEOTIDE MONOMERS AND OLIGONUCLEOTIDES
    Publication number: 20130260460
    Abstract: This invention relates to conformationally locked dinucleotide motifs for exo- and phosphate stabilization. For instance, oligonucleotides can be prepared having one or more of the following formulas (IV-IX).
    Type: Application
    Filed: April 22, 2011
    Publication date: October 3, 2013
    Applicant: ISIS PHARMACEUTICALS INC
    Inventors: Jeremy Lackey, Muthiah Manoharan, Kallanthottathil Rajeev, Ivan Zlatev, Eric E. Swayze, Thazha P. Prakash
  • Carbocyclic alpha-L-bicyclic nucleic acid analogs
    Patent number: 8546556
    Abstract: The present invention provides novel carbocyclic ?-L-bicyclic nucleosides and oligomeric compounds comprising at least one of these carbocyclic ?-L-bicyclic nucleosides. The carbocyclic ?-L-bicyclic nucleosides are useful for enhancing one or more properties of the oligomeric compounds they are incorporated into including nuclease resistance.
    Type: Grant
    Filed: November 21, 2008
    Date of Patent: October 1, 2013
    Assignee: Isis Pharmaceuticals, Inc
    Inventors: Punit P. Seth, Eric E. Swayze
  • METHODS OF DETERMINING POTENCY OF CHEMICALLY-SYNTHESIZED OLIGONUCLEOTIDES
    Publication number: 20130252243
    Abstract: Provided herein are methods for determining potency of RNAi agents. Such methods include, but are not limited to, cell-based and cell-free assays that measure binding of an RNAi agent with Ago2 or that measure Ago2 activity in the presence of such RNAi agents. Also provided are assays that determine potency of RNAi agents by assessing their ability to compete with other RNAi agents, including control RNAi agents, for binding and/or activation of Ago2.
    Type: Application
    Filed: December 21, 2012
    Publication date: September 26, 2013
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Walter F. Lima, Timothy Vickers, Stanley T. Crooke
  • Modulation of SMRT expression
    Patent number: 8541387
    Abstract: Disclosed herein are compounds and methods for decreasing SMRT and treating metabolic and/or cardiovascular diseases in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to SMRT include obesity, diabetes, dyslipidemia, and hypothyroidism.
    Type: Grant
    Filed: May 21, 2009
    Date of Patent: September 24, 2013
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Sanjay K. Pandey, Sanjay Bhanot, Eric G. Marcusson, Susan M. Freier
  • Supports for oligomer synthesis
    Patent number: 8541599
    Abstract: Universal linkers, their facile processes of manufacture and methods of using the same are provided.
    Type: Grant
    Filed: March 7, 2012
    Date of Patent: September 24, 2013
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Vasulinga Ravikumar, Muthiah Manoharan, Andrei P. Guzaev, Zhiwei Wang, Raju K. Kumar
  • Methods for modulating expression of RBP4
    Patent number: 8541388
    Abstract: Methods are provided for modulating RBP4 by administering a RBP4-specific modulator. Also provided are methods for treating cardiovascular and metabolic disorders in a subject or delaying or preventing risk factors thereof through the modulation of RBP4. The present invention is also directed to methods of decreasing lipid levels in a subject or for preventing or delaying the onset of a rise in lipid levels in a subject, comprising administering to said subject a RBP4-specific inhibitor.
    Type: Grant
    Filed: May 21, 2009
    Date of Patent: September 24, 2013
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, Xing-Xian Yu, Sanjay Bhanot
  • Tetrahydropyran nucleic acid analogs
    Patent number: 8536320
    Abstract: The present disclosure describes tetrahydropyran nucleoside analogs, oligomeric compounds prepared therefrom and methods of using the oligomeric compounds. More particularly, novel tetrahydropyran nucleoside analogs are provided having at least one chiral substituent that are expected to be useful for enhancing one or more properties of oligomeric compounds such as nuclease resistance and/or binding affinity. In certain embodiments, the oligomeric compounds are expected to hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.
    Type: Grant
    Filed: February 1, 2010
    Date of Patent: September 17, 2013
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Eric E. Swayze
  • MODULATION OF DYSTROPHIA MYOTONICA-PROTEIN KINASE (DMPK) EXPRESSION
    Publication number: 20130237585
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of a DMPK mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for preferentially reducing CUGexp DMPK RNA, reducing myotonia or reducing spliceopathy in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate type 1 myotonic dystrophy, or a symptom thereof.
    Type: Application
    Filed: July 19, 2011
    Publication date: September 12, 2013
    Applicants: UNIVERSITY OF ROCHESTER, ISIS PHARMACEUTICALS, INC.
    Inventors: C. Frank Bennett, Susan M. Freier, Robert A. MacLeod, Sanjay K. Pandey, Charles A. Thornton, Thurman Wheeler, Seng H. Cheng, Andrew Leger, Bruce M. Wentworth
  • Bicyclic cyclohexitol nucleic acid analogs
    Patent number: 8530640
    Abstract: The present disclosure provides bicyclic cyclohexitol nucleoside analogs of formula I and oligomeric compounds comprising these nucleoside analogs. These bicyclic nucleoside analogs are expected to be useful for enhancing properties of oligomeric compounds including for example nuclease resistance.
    Type: Grant
    Filed: February 6, 2009
    Date of Patent: September 10, 2013
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Punit P. Seth, Michael T. Migawa, Eric E. Swayze, Quanlai Song, Mingming Han, Bruce S. Ross
  • Modulation of apolipoprotein C-III expression
    Patent number: 8530439
    Abstract: Compounds, compositions and methods are provided for modulating the expression of apolipoprotein C-III. The compositions comprise oligonucleotides, targeted to nucleic acid encoding apolipoprotein C-III. Methods of using these compounds for modulation of apolipoprotein C-III expression and for diagnosis and treatment of disease associated with expression of apolipoprotein C-III are provided.
    Type: Grant
    Filed: May 17, 2010
    Date of Patent: September 10, 2013
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Rosanne M. Crooke, Mark J. Graham, Kristina M. Lemonidis, Kenneth W. Dobie
  • MODULATION OF NUCLEAR-RETAINED RNA
    Publication number: 20130225659
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of a nrRNA in an animal. Also provided herein are methods, compounds, and compositions for treating, ameliorating, delaying or reducing a symptom of a disease or disorder associated with a nuclear-retained RNA in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate a disease or condition associated with a nuclear-retained RNA, or a symptom thereof.
    Type: Application
    Filed: July 19, 2011
    Publication date: August 29, 2013
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventor: C. Frank Bennett
  • Modulation of STAT 6 expression
    Patent number: 8518904
    Abstract: Compounds, compositions and methods are provided for modulating the expression of STAT 6. The compositions comprise oligonucleotides, targeted to nucleic acid encoding STAT 6. Methods of using these compounds for modulation of STAT 6 expression and for diagnosis and treatment of disease associated with expression of STAT 6 are provided.
    Type: Grant
    Filed: January 13, 2012
    Date of Patent: August 27, 2013
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: William R. Shanahan, Jr., Susan M. Freier, Kenneth W. Dobie
  • MODULATION OF PHOSPHOENOLPYRUVATE CARBOXYKINASE-MITCHONDRIAL (PEPCK-M) EXPRESSION
    Publication number: 20130217749
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of phosphoenolpyruvate carboxykinase-mitochondrial (PEPCK-M) mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for preventing or decreasing diabetes, obesity, metabolic syndrome, diabetic dyslipidemia, and/or hypertriglyceridemia in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of diabetes, obesity, metabolic syndrome, diabetic dyslipidemia, and/or hypertriglyceridemia, or a symptom thereof.
    Type: Application
    Filed: June 10, 2011
    Publication date: August 22, 2013
    Applicants: Yale University, Isis Pharmaceuticals, Inc.
    Inventors: Sanjay Bhanot, Gerald Shulman
  • Modulation of HIF1? and HIF2? expression
    Patent number: 8513400
    Abstract: Compounds, compositions and methods are provided for modulating the expression of HIF1? and/or HIF2?. The compositions comprise oligonucleotides, targeted to nucleic acid encoding HIF1? and HIF2?. Methods of using these compounds for modulation of HIF1? and/or HIF2? expression and for diagnosis and treatment of disease associated with expression of HIF1? and/or HIF2? are provided.
    Type: Grant
    Filed: December 18, 2009
    Date of Patent: August 20, 2013
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Donna T. Ward, Kenneth W. Dobie, Eric G. Marcusson, Susan M. Freier